Literature DB >> 9245930

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.

S Schreiber1, J Hämling, E Zehnter, S Howaldt, W Daerr, A Raedler, W Kruis.   

Abstract

BACKGROUND: An increasing number of case reports indicate potential nephrotoxicity of 5-aminosalicylic acid (5-ASA), which shares similarities with the chemical structures of both phenacetin and acetylsalicylic acid. AIM: In a point prevalence study the occurrence of sensitive indices indicative of early kidney malfunction was assessed in outpatients with inflammatory bowel disease.
METHODS: Routine indices of kidney function (creatinine clearance, urinary protein content, pH, electrolytes, and microscopy) were investigated in 223 patients with inflammatory bowel disease as well as sensitive markers of glomerular or tubular dysfunction (microproteinuria by SDS polyacrylamide gel electrophoresis (SDS-PAGE), urinary concentrations of N-acetyl-beta-D-glucosaminidase, alpha 1-microglobulin, gamma-glutamyltransferase (GGT), alkaline phosphatase (AP), and albumin). Histories of exposure to 5-ASA were assessed by questionnaire.
RESULTS: Patients receiving high amounts of 5-ASA, both actual as well as on a lifetime basis, showed an increased prevalence of tubular proteinuria by SDS-PAGE. Raised values for urinary AP and GGT indicate proximal tubular epithelial cells as the source. All other kidney function tests were normal. Analysis of covariates indicated strong associations between disease activity and size of 5-ASA doses as well as alterations in kidney tubular function.
CONCLUSION: The possibility exists that high doses of 5-ASA may be associated with proximal tubular proteinuria. This point prevalence study cannot dissect the possible impact of chronic inflammation from high dose 5-ASA treatment and further prospective studies are warranted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9245930      PMCID: PMC1027201          DOI: 10.1136/gut.40.6.761

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  39 in total

1.  Acute interstitial nephritis due to 5-aminosalicylic acid.

Authors:  R P Mehta
Journal:  CMAJ       Date:  1990-11-15       Impact factor: 8.262

2.  Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.

Authors:  T T MacDonald; P Hutchings; M Y Choy; S Murch; A Cooke
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

3.  Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples.

Authors:  S J Schwab; R L Christensen; K Dougherty; S Klahr
Journal:  Arch Intern Med       Date:  1987-05

4.  Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979).

Authors:  U C Dubach; B Rosner; E Pfister
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

5.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

6.  Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.

Authors:  W Kreisel; L M Wolf; W Grotz; M Grieshaber
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-05       Impact factor: 2.566

7.  Nephrotoxic lesions from 5-aminosalicylic Acid.

Authors:  I C Calder; C C Funder; C R Green; K N Ham; J D Tange
Journal:  Br Med J       Date:  1972-01-15

8.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; H G Thiele; A Raedler
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

9.  Microalbuminuria in inflammatory bowel disease.

Authors:  N Mahmud; J Stinson; M A O'Connell; T J Mantle; P W Keeling; J Feely; D G Weir; D Kelleher
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

10.  Tests of renal function in patients with quiescent colitis: effects of drug treatment.

Authors:  S A Riley; D R Lloyd; V Mani
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more
  23 in total

Review 1.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

2.  Urinary protein analysis in pre- and postoperative cancer patients.

Authors:  Kayo Yokomizo; Shiro Iijima; Nobue Sakai; Yuriko Kurihara; Nobuo Hitratsuka; Kagami Nagai; Takehisa Iwai; Kiyoko Shiba
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

3.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

Review 4.  Tubulointerstitial nephritis: diagnosis, treatment, and monitoring.

Authors:  Emily Joyce; Paulina Glasner; Sarangarajan Ranganathan; Agnieszka Swiatecka-Urban
Journal:  Pediatr Nephrol       Date:  2016-05-07       Impact factor: 3.714

5.  Expression of arylamine N-acetyltransferase in human intestine.

Authors:  D Hickman; J Pope; S D Patil; G Fakis; V Smelt; L A Stanley; M Payton; J D Unadkat; E Sim
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

6.  Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment.

Authors:  N Siddique; C Farmer; A F Muller
Journal:  Frontline Gastroenterol       Date:  2014-06-04

7.  Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age.

Authors:  Ravy K Vajravelu; Lawrence Copelovitch; Mark T Osterman; Frank I Scott; Ronac Mamtani; James D Lewis; Michelle R Denburg
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-01       Impact factor: 11.382

8.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Authors:  R A J Ransford; M J S Langman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

9.  Interstitial nephritis from mesalazine: case report and literature review.

Authors:  Lois J Arend; James E Springate
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

10.  What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

Authors:  S A Riley
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.